Skip to main content

Silexion Therapeutics Corp S-3, filed Oct 28, 2026

Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics registers resale of up to 8,813,531 ordinary shares by selling shareholders, including 1,414,266 note shares and 740,224 commercial shares. The shares stem from warrant inducement at $0.2603 per share, conversion of a Moringa Sponsor note and payment to LifeSci for services. The company receives no resale proceeds but may receive cash from warrant exercises. AI summary

S-3 2026-10-28
View Original
Added on October 29, 2026